Dengue Fever
Conditions
Keywords
Dengue, Dengue fever, Dengue Hemorrhagic Fever, Flavivirus
Brief summary
The study is designed to afford a safety and immunogenicity assessment of three Tetravalent Dengue Virus-Purified Inactivated Vaccine(TDENV-PIV) vaccine candidates.
Detailed description
The study is designed to afford a safety and immunogenicity assessment of three Tetravalent Dengue Virus-Purified Inactivated Vaccine(TDENV-PIV) vaccine candidates, each formulated with a different adjuvant: either aluminum hydroxide, AS01E or AS03B (adjuvants used in Glaxo Smith Kline (GSK) Biologicals' hepatitis B candidate vaccine, malaria candidate vaccine and pandemic flu vaccine, respectively). Each vaccine candidate will contain 1 µg of purified virus antigen per each of the four DENV types. Additionally, the study will evaluate an alum adjuvanted TDENV-PIV vaccine candidate containing 4 µg of purified virus antigen per each of the four DENV types. The control group will receive a saline placebo. All experimental vaccinations will be administered according to a 2-dose schedule, 28 days apart.
Interventions
BIOLOGICAL4 µg TDENV-PIV with Alum adjuvant
BIOLOGICAL1 µg TDENV-PIV with AS03B1 adjuvant
BIOLOGICAL1 µg TDENV-PIV with Alum adjuvant
BIOLOGICAL1 µg TDENV-PIV with AS01E1 adjuvant
Sponsors
GlaxoSmithKline
Walter Reed Army Institute of Research (WRAIR)
U.S. Army Medical Research and Development Command
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, etc.) * A male or female between 18 and 39 years of age (inclusive) at the time of consent * Written informed consent obtained from the subject * Healthy subjects as established by medical history and clinical examination before entering into the study * Female subjects of non-childbearing potential (non-childbearing potential is defined as having either a current tubal ligation at least three months prior to enrollment, hysterectomy, ovariectomy, or is post-menopause). See Definition of Terms for adequate contraception. * Female subjects of childbearing potential may be enrolled in the study, if the subject has: * Practiced adequate contraception for 30 days prior to vaccination, and * A negative urine pregnancy test on the day of vaccination, and * Agreed to continue adequate contraception until two months after completion of the vaccination series
Exclusion criteria
* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines/placebo during the period starting 30 days preceding the first dose of study vaccine/placebo and/or planned use during the study period * Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 180 days prior to the first vaccine/placebo dose (for corticosteroids, this will mean prednisone ≥ 20 mg/day or equivalent; inhaled and topical steroids are allowed) * Planned administration or administration of a vaccine/product not foreseen by the study protocol during the period starting 30 days prior to the first dose of vaccine/placebo until after the visit at Day 56 (if influenza activity warrants vaccination of healthy young adults, influenza vaccination will be encouraged and will not lead to study exclusion) * Planned administration of any flavivirus vaccine for the entire study duration * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). * Family history of congenital or hereditary immunodeficiency * History of, or current auto-immune disease * History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine/placebo or related to a study procedure * Major congenital defects or serious chronic illness * History of any neurological disorders or seizures * Acute disease and/or fever (≥37.5°C/99.5°F oral body temperature) at the time of enrollment (a subject with a minor illness, i.e., mild diarrhea, mild upper respiratory infection, etc., without fever, may be enrolled at the discretion of the investigator) * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality,as determined by physical examination or laboratory screening tests * Administration of immunoglobulins and/or any blood products during the period starting 90 days preceding the first dose of study vaccine/placebo or planned administration during the study period * History of chronic alcohol consumption and/or drug abuse * Pregnant or lactating female or female planning to become pregnant or planning to discontinue contraceptive precautions * A planned move to a location that will prohibit participating in the trial until study end for the participant * Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study. * Subject seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV) * Safety laboratory test results that are outside the acceptable values at screening. The following values are not acceptable: * \>110% upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, creatinine, serum urea nitrogen (SUN) and bilirubin (total and direct) * \<100% lower limit of normal (LLN) or \> 120% ULN for hemoglobin, hematocrit and platelet count * \<75% LLN or \>110% ULN for total white blood cell count (WBC) Note that all screening laboratory results must be either within normal limits (WNL) or no more than Grade l not clinically significant (NCS) (LLN=lower limit of normal; ULN= upper limit of normal, WNL= within normal limits, NCS= not clinically significant)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Summary of Subjects With Serious Adverse Events | days 0-392 | Summary of subjects with serious adverse events through out the study |
| Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Days 0-6 post vaccination | Overall incidence of any symptoms (solicited and unsolicited) reported during the 7-day (days 0-6) post vaccination period in TVC population |
| Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Days 0-6 post vaccination | Incidence of General Symptoms (Solicited and Unsolicited) Reported during the 7-day Post Vaccination Period for TVC population. General symptoms are described as fatigue, gastrointestinal symptoms, headache, joint pain, muscle aches and increased temperature (oral). |
| Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Days 0-6 post vaccination | Incidence of Local Symptoms (Solicited and Unsolicited) Reported during the 7-day Post Vaccination Period in TVC population. Local symptoms are described as pain, redness and swelling. |
| Number of Subjects With Adverse Events Within the 28 Day Follow-up | Days 0-28 | Number of subjects with adverse events occurring within days 0-28 following vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | up to month 13 | Geometric Mean Titers (GMTs) of Neutralizing antibody titers specific to each DENV type were measured by a quantitative microneutralization assay with a titer giving 50% reduction in viral infection (MN50) at specified time points. MN50 is specific and sensitive for the detection of anti-DENV neutralizing antibodies. The cut-off for seropositivity was 1: 10 for neutralizing antibody titers measured by MN50 assay. MN50 assay was used to determine initial DENV antibody status of subjects for inclusion in the ATP cohort. PRE = Pre-vaccination, Day 0 visit PI(D7) = Post-dose 1, Day 7 visit PI(D28) = Post-dose 1, Day 28 visit PII(D56) = Post-dose 2, Day 56 visit PII(M4) = Post-dose 2, Month 4 visit PII(M7) = Post-dose 2, Month 7 visit PII(M10) = Post-dose 2, Month 10 visit PII(M13) = Post-dose 2, Month 13 visit |
| Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | up to month 13 | Number of subjects showing Monovalent, bivalent, trivalent and tetravalent response for neutralizing antibodies by Microneutralization Titer (giving 50% reduction in viral infection (MN50)) in the TVC population. PI(D7) = Post-dose 1, Day 7 visit PI(D28) = Post-dose 1, Day 28 visit PII(D56) = Post-dose 2, Day 56 visit PII(M4) = Post-dose 2, Month 4 visit PII(M7) = Post-dose 2, Month 7 visit PII(M10) = Post-dose 2, Month 10 visit PII(M13) = Post-dose 2, Month 13 visit |
| Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | day 56 visit | The percentage of subjects with hematological and biochemical laboratory values within and outside the normal ranges and with different grade of AE were tabulated with exact 95% CI at baseline and at each specified timepoint. Safety laboratory assays were performed at a WRAIR-designated Clinical Laboratory Improvement Amendments-certified laboratory. All safety-related clinical laboratory values were reviewed and all abnormal values were assessed by the investigators as clinically significant or not, with respect to safety. PRE = Pre-vaccination, Day 0 visit PI(D7) = Post-dose 1, Day 7 visit PI(D28) = Post-dose 1, Day 28 visit PII(D35) = Post-dose 2, Day 35 visit PII(D56) = Post-dose 2, Day 56 visit PII(M4) = Post-dose 2, Month 4 visit PII(M7) = Post-dose 2, Month 7 visit PII(M10) = Post-dose 2, Month 10 visit PII(M13) = Post-dose 2, Month 13 visit |
Countries
United States
Participant flow
Recruitment details
This study enrolled healthy male and non-pregnant, non-breast-feeding, female subjects between the ages of 18 and 39 (inclusive). Subjects were enrolled at the CTC, WRAIR, Silver Spring, Maryland, US. Subjects were not screened for prior flavivirus infection.
Participants by arm
| Arm | Count |
|---|---|
| TDENV-PIV alum1 1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
1 µg TDENV-PIV with Alum adjuvant | 20 |
| TDENV-PIV alum4 4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
4 µg TDENV-PIV with Alum adjuvant | 20 |
| TDENV-PIV AS01E1 1 µg TDENV-PIV with AS01E1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
1 µg TDENV-PIV with AS01E1 adjuvant | 20 |
| TDENV-PIV AS03B1 1 µg TDENV-PIV with AS03B1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
1 µg TDENV-PIV with AS03B1 adjuvant | 20 |
| Placebo Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
Phosphate buffered saline | 20 |
| Total | 100 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 1 | 1 | 1 | 1 | 0 |
| Overall Study | Moved from study area | 1 | 0 | 0 | 2 | 0 |
| Overall Study | Serious Adverse Event | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Total | Placebo | TDENV-PIV AS03B1 | TDENV-PIV AS01E1 | TDENV-PIV alum4 | TDENV-PIV alum1 |
|---|---|---|---|---|---|---|
| Age, Continuous | 27.8 years STANDARD_DEVIATION 5.62 | 28.3 years STANDARD_DEVIATION 5.47 | 28.4 years STANDARD_DEVIATION 5.56 | 28.0 years STANDARD_DEVIATION 6.86 | 26.1 years STANDARD_DEVIATION 4.55 | 28.2 years STANDARD_DEVIATION 5.68 |
| Race/Ethnicity, Customized American Indian or Alaskan Native | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian-Central/South Asian | 4 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian-East Asian | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Other | 8 Participants | 2 Participants | 1 Participants | 2 Participants | 2 Participants | 1 Participants |
| Race/Ethnicity, Customized White-Caucasian/European | 34 Participants | 8 Participants | 8 Participants | 4 Participants | 4 Participants | 10 Participants |
| Region of Enrollment United States | 100 participants | 20 participants | 20 participants | 20 participants | 20 participants | 20 participants |
| Sex: Female, Male Female | 43 Participants | 7 Participants | 11 Participants | 7 Participants | 7 Participants | 11 Participants |
| Sex: Female, Male Male | 57 Participants | 13 Participants | 9 Participants | 13 Participants | 13 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 20 | 0 / 20 | 0 / 20 | 1 / 20 | 0 / 20 |
| other Total, other adverse events | 12 / 20 | 9 / 20 | 12 / 20 | 15 / 20 | 14 / 20 |
| serious Total, serious adverse events | 0 / 20 | 0 / 20 | 1 / 20 | 3 / 20 | 0 / 20 |
Outcome results
Primary
Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC)
Overall incidence of any symptoms (solicited and unsolicited) reported during the 7-day (days 0-6) post vaccination period in TVC population
Time frame: Days 0-6 post vaccination
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TDENV-PIV alum1 | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 1 | 8 AEs |
| TDENV-PIV alum1 | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 2 | 7 AEs |
| TDENV-PIV alum4 | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 1 | 12 AEs |
| TDENV-PIV alum4 | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 2 | 9 AEs |
| TDENV-PIV AS01E1 | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 1 | 15 AEs |
| TDENV-PIV AS01E1 | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 2 | 15 AEs |
| TDENV-PIV AS03B1 | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 2 | 15 AEs |
| TDENV-PIV AS03B1 | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 1 | 20 AEs |
| Placebo | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 1 | 13 AEs |
| Placebo | Incidence of Any Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period. Total Vaccinated Cohort (TVC) | Dose 2 | 11 AEs |
Primary
Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC)
Incidence of General Symptoms (Solicited and Unsolicited) Reported during the 7-day Post Vaccination Period for TVC population. General symptoms are described as fatigue, gastrointestinal symptoms, headache, joint pain, muscle aches and increased temperature (oral).
Time frame: Days 0-6 post vaccination
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TDENV-PIV alum1 | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 8 AEs |
| TDENV-PIV alum1 | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 2 AEs |
| TDENV-PIV alum4 | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 10 AEs |
| TDENV-PIV alum4 | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 7 AEs |
| TDENV-PIV AS01E1 | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 12 AEs |
| TDENV-PIV AS01E1 | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 10 AEs |
| TDENV-PIV AS03B1 | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 14 AEs |
| TDENV-PIV AS03B1 | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 14 AEs |
| Placebo | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 12 AEs |
| Placebo | Incidence of General Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 11 AEs |
Primary
Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC)
Incidence of Local Symptoms (Solicited and Unsolicited) Reported during the 7-day Post Vaccination Period in TVC population. Local symptoms are described as pain, redness and swelling.
Time frame: Days 0-6 post vaccination
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TDENV-PIV alum1 | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 5 AEs |
| TDENV-PIV alum1 | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 6 AEs |
| TDENV-PIV alum4 | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 7 AEs |
| TDENV-PIV alum4 | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 6 AEs |
| TDENV-PIV AS01E1 | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 14 AEs |
| TDENV-PIV AS01E1 | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 15 AEs |
| TDENV-PIV AS03B1 | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 17 AEs |
| TDENV-PIV AS03B1 | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 12 AEs |
| Placebo | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 2 | 2 AEs |
| Placebo | Incidence of Local Symptoms (Solicited and Unsolicited) Reported During the 7-day Post Vaccination Period, Total Vaccinated Cohort (TVC) | Dose 1 | 2 AEs |
Primary
Number of Subjects With Adverse Events Within the 28 Day Follow-up
Number of subjects with adverse events occurring within days 0-28 following vaccination
Time frame: Days 0-28
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TDENV-PIV alum1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Tachycardia | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Upper respiratory tract infection | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | White blood cell count increased | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Nasopharyngitis | 2 Participants |
| TDENV-PIV alum1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Neutrophil count decreased | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Bradycardia | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Chills | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Subjects with any AEs | 10 Participants |
| TDENV-PIV alum4 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Subjects with any AEs | 9 Participants |
| TDENV-PIV alum4 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Neutrophil count decreased | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Chills | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Bradycardia | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Upper respiratory tract infection | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Nasopharyngitis | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | White blood cell count increased | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Tachycardia | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Subjects with any AEs | 10 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Upper respiratory tract infection | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Nasopharyngitis | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Chills | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Neutrophil count decreased | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Bradycardia | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Tachycardia | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | White blood cell count increased | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Bradycardia | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | White blood cell count increased | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Tachycardia | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Subjects with any AEs | 14 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Nasopharyngitis | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Chills | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Neutrophil count decreased | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Upper respiratory tract infection | 3 Participants |
| Placebo | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Neutrophil count decreased | 3 Participants |
| Placebo | Number of Subjects With Adverse Events Within the 28 Day Follow-up | White blood cell count increased | 2 Participants |
| Placebo | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Subjects with any AEs | 15 Participants |
| Placebo | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Upper respiratory tract infection | 0 Participants |
| Placebo | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Nasopharyngitis | 2 Participants |
| Placebo | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Bradycardia | 2 Participants |
| Placebo | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Chills | 0 Participants |
| Placebo | Number of Subjects With Adverse Events Within the 28 Day Follow-up | Tachycardia | 2 Participants |
Primary
Summary of Subjects With Serious Adverse Events
Summary of subjects with serious adverse events through out the study
Time frame: days 0-392
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TDENV-PIV alum1 | Summary of Subjects With Serious Adverse Events | Miscarriage | 0 Participants |
| TDENV-PIV alum1 | Summary of Subjects With Serious Adverse Events | Asthma | 0 Participants |
| TDENV-PIV alum1 | Summary of Subjects With Serious Adverse Events | Gunshot wound | 0 Participants |
| TDENV-PIV alum1 | Summary of Subjects With Serious Adverse Events | Worsening abdominla discomfort | 0 Participants |
| TDENV-PIV alum4 | Summary of Subjects With Serious Adverse Events | Asthma | 0 Participants |
| TDENV-PIV alum4 | Summary of Subjects With Serious Adverse Events | Miscarriage | 0 Participants |
| TDENV-PIV alum4 | Summary of Subjects With Serious Adverse Events | Gunshot wound | 0 Participants |
| TDENV-PIV alum4 | Summary of Subjects With Serious Adverse Events | Worsening abdominla discomfort | 0 Participants |
| TDENV-PIV AS01E1 | Summary of Subjects With Serious Adverse Events | Miscarriage | 0 Participants |
| TDENV-PIV AS01E1 | Summary of Subjects With Serious Adverse Events | Gunshot wound | 0 Participants |
| TDENV-PIV AS01E1 | Summary of Subjects With Serious Adverse Events | Asthma | 1 Participants |
| TDENV-PIV AS01E1 | Summary of Subjects With Serious Adverse Events | Worsening abdominla discomfort | 0 Participants |
| TDENV-PIV AS03B1 | Summary of Subjects With Serious Adverse Events | Miscarriage | 1 Participants |
| TDENV-PIV AS03B1 | Summary of Subjects With Serious Adverse Events | Asthma | 0 Participants |
| TDENV-PIV AS03B1 | Summary of Subjects With Serious Adverse Events | Worsening abdominla discomfort | 1 Participants |
| TDENV-PIV AS03B1 | Summary of Subjects With Serious Adverse Events | Gunshot wound | 1 Participants |
| Placebo | Summary of Subjects With Serious Adverse Events | Miscarriage | 0 Participants |
| Placebo | Summary of Subjects With Serious Adverse Events | Asthma | 0 Participants |
| Placebo | Summary of Subjects With Serious Adverse Events | Worsening abdominla discomfort | 0 Participants |
| Placebo | Summary of Subjects With Serious Adverse Events | Gunshot wound | 0 Participants |
Secondary
Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP)
Geometric Mean Titers (GMTs) of Neutralizing antibody titers specific to each DENV type were measured by a quantitative microneutralization assay with a titer giving 50% reduction in viral infection (MN50) at specified time points. MN50 is specific and sensitive for the detection of anti-DENV neutralizing antibodies. The cut-off for seropositivity was 1: 10 for neutralizing antibody titers measured by MN50 assay. MN50 assay was used to determine initial DENV antibody status of subjects for inclusion in the ATP cohort. PRE = Pre-vaccination, Day 0 visit PI(D7) = Post-dose 1, Day 7 visit PI(D28) = Post-dose 1, Day 28 visit PII(D56) = Post-dose 2, Day 56 visit PII(M4) = Post-dose 2, Month 4 visit PII(M7) = Post-dose 2, Month 7 visit PII(M10) = Post-dose 2, Month 10 visit PII(M13) = Post-dose 2, Month 13 visit
Time frame: up to month 13
Population: subjects with available data
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(D56) | 64.3 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PRE | 5.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PRE | 5.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M7) | 5.9 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M13) | 7.9 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M7) | 6.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D28) | 5.3 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D28) | 5.3 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M13) | 5.7 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PRE | 5.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M10) | 5.8 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D7) | 5.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M7) | 5.8 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D7) | 5.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D7) | 5.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den: PII(M13) | 7.2 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M4) | 17.8 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PRE | 5.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M4) | 13.2 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D28) | 5.2 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M10) | 7.3 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M4) | 5.9 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M13) | 5.3 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(D56) | 65.6 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(D56) | 44.2 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M10) | 6.4 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(D56) | 26.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M10) | 6.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D28) | 7.4 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M4) | 7.9 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D7) | 5.0 GMT |
| TDENV-PIV alum1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M7) | 7.2 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D28) | 14.7 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D28) | 16.7 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M7) | 14.0 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PRE | 5.0 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M10) | 9.4 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D7) | 5.0 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den: PII(M13) | 9.4 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M7) | 9.1 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PRE | 5.0 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D7) | 5.0 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M13) | 9.5 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M10) | 7.1 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M7) | 13.6 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M10) | 9.1 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M13) | 7.3 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M10) | 14.5 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(D56) | 162.7 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M4) | 129.6 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(D56) | 180.4 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M13) | 13.2 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M7) | 13.4 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D7) | 5.0 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PRE | 5.0 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D28) | 8.2 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D7) | 5.8 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M4) | 60.4 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D28) | 18.1 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PRE | 5.0 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(D56) | 159.3 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M4) | 12.9 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(D56) | 188.9 GMT |
| TDENV-PIV alum4 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M4) | 23.1 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D7) | 5.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D28) | 6.7 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(D56) | 201.7 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M7) | 21.5 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M4) | 17.6 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M7) | 7.5 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M10) | 11.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M13) | 9.3 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M10) | 35.7 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M13) | 31.2 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PRE | 5.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D7) | 5.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D28) | 19.8 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(D56) | 361.4 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M4) | 46.6 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M7) | 19.9 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D28) | 32.4 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M10) | 43.6 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den: PII(M13) | 27.3 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PRE | 5.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D7) | 5.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(D56) | 335.8 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D28) | 20.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(D56) | 431.5 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M4) | 135.4 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M7) | 21.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M10) | 36.7 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M4) | 182.8 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M13) | 36.7 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PRE | 5.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PRE | 5.0 GMT |
| TDENV-PIV AS01E1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D7) | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(D56) | 373.3 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M4) | 247.6 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(D56) | 495.5 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D28) | 15.9 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D7) | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D7) | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M7) | 32.8 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M4) | 129.6 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D7) | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PRE | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M13) | 24.9 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M4) | 29.8 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M7) | 29.5 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M10) | 24.3 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M13) | 8.2 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M10) | 6.8 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(D56) | 462.3 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M10) | 20.7 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PRE | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PRE | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PRE | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den: PII(M13) | 17.1 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D28) | 28.9 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M10) | 16.8 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M7) | 15.2 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D7) | 5.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D28) | 7.4 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M7) | 22.6 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M13) | 24.0 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D28) | 14.1 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(D56) | 577.8 GMT |
| TDENV-PIV AS03B1 | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M4) | 47.2 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M13) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PRE | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D7) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PI(D28) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(D56) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M4) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M7) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M10) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den1: PII(M13) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PRE | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D7) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PI(D28) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(D56) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M4) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M7) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den2: PII(M10) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den: PII(M13) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PRE | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D7) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PI(D28) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(D56) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M4) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M7) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M10) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den3: PII(M13) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PRE | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D7) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PI(D28) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(D56) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M4) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M7) | 5.0 GMT |
| Placebo | Geometric Mean Titers (GMTs) of Neutralizing Antibody Titers Specific to Each DENV Type - According to Protocol Population (ATP) | MN Ab Den4: PII(M10) | 5.0 GMT |
Secondary
Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC)
Number of subjects showing Monovalent, bivalent, trivalent and tetravalent response for neutralizing antibodies by Microneutralization Titer (giving 50% reduction in viral infection (MN50)) in the TVC population. PI(D7) = Post-dose 1, Day 7 visit PI(D28) = Post-dose 1, Day 28 visit PII(D56) = Post-dose 2, Day 56 visit PII(M4) = Post-dose 2, Month 4 visit PII(M7) = Post-dose 2, Month 7 visit PII(M10) = Post-dose 2, Month 10 visit PII(M13) = Post-dose 2, Month 13 visit
Time frame: up to month 13
Population: subjects with available results for all four DENV-types (without missing N antibody titer)
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Bivalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Trivalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Trivalent | 1 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Monovalent | 6 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Tetravalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Trivalent | 7 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | None | 20 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Monovalent | 2 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Monovalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Trivalent | 1 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | None | 5 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Bivalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | None | 12 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Bivalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Trivalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Tetravalent | 1 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Tetravalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Tetravalent | 12 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | None | 14 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Tetravalent | 3 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Trivalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | None | 15 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Monovalent | 4 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Bivalent | 1 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Tetravalent | 2 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Tetravalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Monovalent | 5 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | None | 12 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Trivalent | 4 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Bivalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Trivalent | 1 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | None | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Tetravalent | 1 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | None | 20 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Monovalent | 4 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Bivalent | 2 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Monovalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Bivalent | 1 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Bivalent | 0 Participants |
| TDENV-PIV alum1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Monovalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | None | 2 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Monovalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Bivalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Trivalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Monovalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Trivalent | 3 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Monovalent | 3 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Trivalent | 2 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Tetravalent | 1 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Monovalent | 4 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Trivalent | 4 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Monovalent | 2 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Bivalent | 4 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | None | 18 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Tetravalent | 10 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Tetravalent | 4 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | None | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Bivalent | 5 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Monovalent | 1 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Monovalent | 6 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Bivalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Trivalent | 3 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Monovalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Bivalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Tetravalent | 4 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | None | 5 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Tetravalent | 4 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Bivalent | 4 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Trivalent | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Bivalent | 2 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | None | 19 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Tetravalent | 18 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | None | 0 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Tetravalent | 1 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Trivalent | 5 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Tetravalent | 6 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Bivalent | 3 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | None | 3 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | None | 3 Participants |
| TDENV-PIV alum4 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Trivalent | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | None | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Trivalent | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Monovalent | 5 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Monovalent | 3 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Bivalent | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Tetravalent | 11 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Trivalent | 6 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Bivalent | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Tetravalent | 5 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | None | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | None | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Monovalent | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Monovalent | 4 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Bivalent | 4 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Tetravalent | 6 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Trivalent | 3 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Trivalent | 7 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Tetravalent | 8 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | None | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | None | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Bivalent | 5 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Bivalent | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Trivalent | 5 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | None | 16 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Bivalent | 3 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Monovalent | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Monovalent | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Bivalent | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Trivalent | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Tetravalent | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | None | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | None | 16 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Trivalent | 6 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Monovalent | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Monovalent | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Bivalent | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Tetravalent | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Trivalent | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Tetravalent | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Tetravalent | 5 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Monovalent | 3 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Monovalent | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Tetravalent | 5 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Bivalent | 3 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Trivalent | 5 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Tetravalent | 7 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | None | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Monovalent | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Bivalent | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Trivalent | 7 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Tetravalent | 4 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | None | 3 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Bivalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Trivalent | 6 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | None | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Monovalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Bivalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Trivalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Tetravalent | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | None | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Monovalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Bivalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Trivalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Tetravalent | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | None | 4 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Monovalent | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Bivalent | 4 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Trivalent | 5 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Tetravalent | 3 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | None | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Monovalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Bivalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Trivalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Tetravalent | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | None | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Monovalent | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Bivalent | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Trivalent | 3 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Tetravalent | 14 Participants |
| TDENV-PIV AS03B1 | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | None | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Trivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Trivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Tetravalent | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Trivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Bivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Bivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Tetravalent | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | Monovalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D7) | None | 18 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Tetravalent | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Monovalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | None | 17 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Trivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Bivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | Monovalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Monovalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Monovalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PRE | None | 18 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Trivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Bivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | None | 17 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Bivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | None | 17 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Tetravalent | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Trivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Tetravalent | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Trivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | Bivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M10) | None | 17 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M7) | Tetravalent | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M13) | Monovalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Monovalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | None | 18 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Tetravalent | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Trivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(M4) | Tetravalent | 2 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PII(56) | Bivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Bivalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | Monovalent | 0 Participants |
| Placebo | Number of Subject Showing Monovalent, Bivalent, Trivalent and Tetravalent Response for Neutralizing Antibodies - Total Vaccinated Cohort (TVC) | PI(D28) | None | 18 Participants |
Secondary
Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit
The percentage of subjects with hematological and biochemical laboratory values within and outside the normal ranges and with different grade of AE were tabulated with exact 95% CI at baseline and at each specified timepoint. Safety laboratory assays were performed at a WRAIR-designated Clinical Laboratory Improvement Amendments-certified laboratory. All safety-related clinical laboratory values were reviewed and all abnormal values were assessed by the investigators as clinically significant or not, with respect to safety. PRE = Pre-vaccination, Day 0 visit PI(D7) = Post-dose 1, Day 7 visit PI(D28) = Post-dose 1, Day 28 visit PII(D35) = Post-dose 2, Day 35 visit PII(D56) = Post-dose 2, Day 56 visit PII(M4) = Post-dose 2, Month 4 visit PII(M7) = Post-dose 2, Month 7 visit PII(M10) = Post-dose 2, Month 10 visit PII(M13) = Post-dose 2, Month 13 visit
Time frame: day 56 visit
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 1-2 | 2 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Below LLN | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Below LLN | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Normal | 18 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Above ULN | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Below LLN | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Normal | 18 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Normal | 18 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 1-2 | 2 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 1-2 | 2 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 1-2 | 3 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Normal | 16 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 1-2 | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Normal | 17 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Below LLN | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Normal | 16 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 1-2 | 3 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Below LLN | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 1-2 | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Below LLN | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 1-2 | 4 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Below LLN | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Normal | 17 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Normal | 16 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 1-2 | 3 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Normal | 17 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Below LLN | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Below LLN | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Normal | 17 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Above ULN | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 1-2 | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 1-2 | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 1-2 | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Below LLN | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Normal | 17 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Normal | 17 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 1-2 | 00 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Normal | 17 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Below LLN | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 1-2 | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Normal | 18 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Below LLN | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Normal | 15 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Below LLN | 2 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Missing | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Below LLN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Normal | 20 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Normal | 17 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Normal | 19 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Above ULN | 0 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Missing | 1 Participants |
| TDENV-PIV alum4 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Normal | 17 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Above ULN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Below LLN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Above ULN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 1-2 | 3 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Normal | 17 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Above ULN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 1-2 | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Normal | 17 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Above ULN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Below LLN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Normal | 17 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 1-2 | 3 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Above ULN | 2 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 3 or more | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Missing | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Normal | 18 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Normal | 20 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Below LLN | 1 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS01E1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 1-2 | 3 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Above ULN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Above ULN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Below LLN | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Normal | 16 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 1-2 | 3 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Below LLN | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Normal | 17 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 1-2 | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Normal | 17 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 1-2 | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Above ULN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Above ULN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Normal | 17 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Below LLN | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 1-2 | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 1-2 | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 1-2 | 2 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Normal | 17 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 1-2 | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Normal | 20 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Normal | 18 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Missing | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 3 or more | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Normal | 19 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Above ULN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 1-2 | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Missing | 1 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Below LLN | 0 Participants |
| TDENV-PIV AS03B1 | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 1-2 | 2 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Normal | 18 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D28) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: SCR | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 1-2 | 3 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Normal | 17 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Normal | 18 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 1-2 | 3 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Normal | 15 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Grade 1-2 | 2 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Normal | 18 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Grade 1-2 | 5 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D56) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Normal | 17 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Above ULN | 2 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 3 or more | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D28) | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Normal | 18 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PI(D7) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Normal | 18 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Grade 1-2 | 2 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D7) | Above ULN | 2 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D56) | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PRE | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Normal | 15 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilibrubin: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D56) | Above ULN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PRE | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PRE | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D35) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PI(D28) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | AP: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PI(D28) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Normal | 19 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D35) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: SCR | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Above ULN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PII(D35) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Hemoglobin: PII(D56) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Normal | 17 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PII(D35) | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Normal | 17 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PRE | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Grade 1-2 | 3 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Eosinophils: PII(D56) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: SCR | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Neutrophils: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Below LLN | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D35) | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ALAT: PI(D7) | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PII(D56) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: PI(D28) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Grade 1-2 | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: SCR | Normal | 20 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D35) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | BUN: PI(D7) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PII(D56) | Below LLN | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Total bilirubin: PI(D7) | Grade 3 or more | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Creatinine: PII(D35) | Grade 1-2 | 1 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | White blood cells: PII(D56) | Grade 1-2 | 3 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Platelets: SCR | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | Lymphocytes: PI(D7) | Missing | 0 Participants |
| Placebo | Number of Subjects With Laboratory Values Within and Outside the Normal Ranges and With Different Grade of Adverse Event From Screening to Day 56 Visit | ASAT: PRE | Above ULN | 0 Participants |